prochlorperazine has been researched along with Neoplasms in 44 studies
Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)
prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral granisetron is well tolerated and more effective than prochlorperazine in preventing nausea and vomiting for up to 48 h following treatment with moderately emetogenic chemotherapy." | 9.09 | Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. ( Blackburn, LM; Burris, HA; Friedman, CJ; Gruben, D; Yocom, K, 2000) |
| "This double-blind randomized cross-over study was conducted to compare the safety and efficacy of high-dose prochlorperazine infusion and dexamethasone (HDPD) with an effective and safe combination of high-dose metoclopramide and dexamethasone (HDMD) in controlling cisplatin-induced emesis." | 9.07 | A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis. ( Akhtar, SS; Bano, ZA; Bhat, GM; Bhat, MA, 1991) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 7.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| "The incidence of nausea induced by oxycodone with prochlorperazine was 18." | 7.81 | Incidence of nausea and vomiting induced by oxycodone administered with prochlorperazine in Japanese cancer patients. ( Aoki, Y; Kanazawa, Y; Uchida, E; Yamada, T, 2015) |
| "Prochlorperazine is often used to prevent opioid-induced nausea; however, this drug causes extrapyramidal symptoms." | 7.79 | [A study on the antiemetic effect and extrapyramidal symptoms of prochlorperazine versus perospirone for the control of nausea and vomiting due to opioid introduction]. ( Kono, B; Kurosawa, H; Takei, D; Yomiya, K, 2013) |
| "Nausea was absent in 40 of 55 patients receiving THC, eight of 55 patients receiving prochlorperazine, and five of 55 in the placebo group." | 6.65 | Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. ( Bloome, B; McKernan, JF; Orr, LE, 1980) |
| "Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0." | 6.65 | Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. ( Bordin, LA; Braun, DW; Braun, TJ; Gralla, RJ; Itri, LM; Kelsen, DP; Pisko, SE; Squillante, AE; Young, CW, 1981) |
| "Oral granisetron is well tolerated and more effective than prochlorperazine in preventing nausea and vomiting for up to 48 h following treatment with moderately emetogenic chemotherapy." | 5.09 | Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. ( Blackburn, LM; Burris, HA; Friedman, CJ; Gruben, D; Yocom, K, 2000) |
| "This double-blind randomized cross-over study was conducted to compare the safety and efficacy of high-dose prochlorperazine infusion and dexamethasone (HDPD) with an effective and safe combination of high-dose metoclopramide and dexamethasone (HDMD) in controlling cisplatin-induced emesis." | 5.07 | A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis. ( Akhtar, SS; Bano, ZA; Bhat, GM; Bhat, MA, 1991) |
| "Delta-9-tetrahydrocannabinol (THC) and prochlorperazine (Compazine) were found to be equally efficacious in reducing nausea and vomiting associated with cancer chemotherapy across a wide range of chemotherapeutic regimens and tumor types." | 5.05 | Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. ( Andrysiak, T; Fairbanks, L; Goodnight, J; Jamison, K; Sarna, G; Ungerleider, JT, 1982) |
| "Lorazepam was compared to placebo to assess its control of nausea and vomiting in patients receiving cytotoxic chemotherapy and prochlorperazine." | 5.05 | Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine. ( Bingham, J; Bishop, JF; Cooper, IA; Hillcoat, BL; Long, M; Matthews, JP; Olver, IN; Wolf, MM, 1984) |
| "Two double-blind, crossover trials comparing the antiemetic effectiveness of nabilone, a new synthetic cannabinoid, with that of prochlorperazine were conducted in patients with severe nausea and vomiting associated with anticancer chemotherapy." | 5.04 | Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. ( Chester, AB; Dean, JC; Dorr, RT; Einhorn, LH; Furnas, B; Herman, TS; Jones, SE; Leigh, SA; Moon, TE; Nagy, C; Williams, SD, 1979) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 3.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| "The incidence of nausea induced by oxycodone with prochlorperazine was 18." | 3.81 | Incidence of nausea and vomiting induced by oxycodone administered with prochlorperazine in Japanese cancer patients. ( Aoki, Y; Kanazawa, Y; Uchida, E; Yamada, T, 2015) |
| "Plasma prochlorperazine concentration and oxycodone daily dose were not associated with the incidences of nausea and vomiting." | 3.80 | Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients. ( Kagawa, Y; Kawakami, J; Naito, T; Ohnishi, K; Tashiro, M, 2014) |
| "Prochlorperazine is often used to prevent opioid-induced nausea; however, this drug causes extrapyramidal symptoms." | 3.79 | [A study on the antiemetic effect and extrapyramidal symptoms of prochlorperazine versus perospirone for the control of nausea and vomiting due to opioid introduction]. ( Kono, B; Kurosawa, H; Takei, D; Yomiya, K, 2013) |
| " Large interpatient variation in peak PCZ plasma levels (91-3215 ng/ml) was seen, with the plasma half-life (t1/2 alpha) being approximately 57 min in patients given 135-180 mg/m2 PCZ." | 2.67 | Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ( Auguste, ME; Benedetto, PW; Duncan, RC; Krishan, A; McPhee, GV; Samy, TS; Sauerteig, A; Sridhar, KS, 1994) |
| " Pharmacokinetic analysis indicated a large interpatient variation in peak plasma PCZ levels that ranged from 95 to 1100 ng/ml." | 2.67 | Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. ( Anac, SY; Ardalan, B; Benedetto, PW; Duncan, RC; Krishan, A; McPhee, G; Samy, TS; Sauerteig, A; Sridhar, KS; Wellham, LL, 1993) |
| "Nausea was absent in 40 of 55 patients receiving THC, eight of 55 patients receiving prochlorperazine, and five of 55 in the placebo group." | 2.65 | Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. ( Bloome, B; McKernan, JF; Orr, LE, 1980) |
| "Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0." | 2.65 | Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. ( Bordin, LA; Braun, DW; Braun, TJ; Gralla, RJ; Itri, LM; Kelsen, DP; Pisko, SE; Squillante, AE; Young, CW, 1981) |
| "Methods Forty-eight cancer patients treated with oral prochlorperazine were enrolled." | 1.48 | Influence of cytochrome P450 genotype on the plasma disposition of prochlorperazine metabolites and their relationships with clinical responses in cancer patients. ( Kagawa, Y; Kawakami, J; Naito, T; Tashiro, M, 2018) |
| " Thus, controlling the adverse side effects associated with radiation therapy is critical to optimal patient care." | 1.29 | Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. ( Priestman, TJ, 1996) |
| " No adverse effects were observed in our patients." | 1.28 | Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. ( Ford, C; Nahata, MC; Ruymann, FB, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (45.45) | 18.7374 |
| 1990's | 9 (20.45) | 18.2507 |
| 2000's | 5 (11.36) | 29.6817 |
| 2010's | 8 (18.18) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Chew, HY | 1 |
| De Lima, PO | 1 |
| Gonzalez Cruz, JL | 1 |
| Banushi, B | 1 |
| Echejoh, G | 1 |
| Hu, L | 1 |
| Joseph, SR | 1 |
| Lum, B | 1 |
| Rae, J | 1 |
| O'Donnell, JS | 1 |
| Merida de Long, L | 1 |
| Okano, S | 1 |
| King, B | 1 |
| Barry, R | 1 |
| Moi, D | 1 |
| Mazzieri, R | 1 |
| Thomas, R | 1 |
| Souza-Fonseca-Guimaraes, F | 1 |
| Foote, M | 1 |
| McCluskey, A | 1 |
| Robinson, PJ | 1 |
| Frazer, IH | 1 |
| Saunders, NA | 1 |
| Parton, RG | 1 |
| Dolcetti, R | 1 |
| Cuff, K | 1 |
| Martin, JH | 1 |
| Panizza, B | 1 |
| Walpole, E | 2 |
| Wells, JW | 1 |
| Simpson, F | 1 |
| Otręba, M | 1 |
| Kośmider, L | 1 |
| Tashiro, M | 3 |
| Naito, T | 3 |
| Kagawa, Y | 3 |
| Kawakami, J | 3 |
| Yomiya, K | 1 |
| Takei, D | 1 |
| Kurosawa, H | 1 |
| Kono, B | 1 |
| Ohnishi, K | 1 |
| Yamada, T | 1 |
| Kanazawa, Y | 1 |
| Aoki, Y | 1 |
| Uchida, E | 1 |
| Tsukuura, H | 1 |
| Ando, Y | 1 |
| Gyawali, B | 1 |
| Matsumoto, M | 1 |
| Sugishita, M | 1 |
| Honda, K | 1 |
| Urakawa, H | 1 |
| Maeda, O | 1 |
| Hasegawa, Y | 1 |
| Smith, LA | 1 |
| Azariah, F | 1 |
| Lavender, VT | 1 |
| Stoner, NS | 1 |
| Bettiol, S | 1 |
| Waqar, SN | 1 |
| Mann, J | 1 |
| Baggstrom, MQ | 1 |
| Waqar, MA | 1 |
| Chitneni, P | 1 |
| Williams, K | 1 |
| Gao, F | 1 |
| Morgensztern, D | 1 |
| Govindan, R | 1 |
| FAGNANO, G | 1 |
| CRISTOFARI, U | 1 |
| DE MARCHI, A | 1 |
| GATTO, A | 1 |
| WILLHEIM, R | 1 |
| O'MALLEY, BB | 1 |
| FLUSS, P | 1 |
| DICKSON, J | 1 |
| AUBER, M | 1 |
| POTTS, AM | 1 |
| Kawanishi, C | 1 |
| Onishi, H | 1 |
| Kato, D | 1 |
| Kishida, I | 1 |
| Furuno, T | 1 |
| Wada, M | 1 |
| Hirayasu, Y | 1 |
| Kotlarek-Haus, S | 1 |
| Orzechowska-Juzwenko, K | 1 |
| Gabryś, K | 1 |
| Orr, LE | 1 |
| McKernan, JF | 1 |
| Bloome, B | 1 |
| Ungerleider, JT | 1 |
| Andrysiak, T | 1 |
| Fairbanks, L | 1 |
| Goodnight, J | 1 |
| Sarna, G | 1 |
| Jamison, K | 1 |
| Bishop, JF | 2 |
| Olver, IN | 1 |
| Wolf, MM | 2 |
| Matthews, JP | 2 |
| Long, M | 1 |
| Bingham, J | 1 |
| Hillcoat, BL | 1 |
| Cooper, IA | 1 |
| Sallan, SE | 1 |
| Cronin, C | 1 |
| Zelen, M | 1 |
| Zinberg, NE | 1 |
| Winokur, SH | 1 |
| Baker, JJ | 1 |
| Lokey, JL | 1 |
| Price, NA | 1 |
| Bowen, J | 1 |
| Gralla, RJ | 1 |
| Itri, LM | 1 |
| Pisko, SE | 1 |
| Squillante, AE | 1 |
| Kelsen, DP | 1 |
| Braun, DW | 1 |
| Bordin, LA | 1 |
| Braun, TJ | 1 |
| Young, CW | 1 |
| Sridhar, KS | 3 |
| Krishan, A | 3 |
| Samy, TS | 2 |
| Duncan, RC | 2 |
| Sauerteig, A | 2 |
| McPhee, GV | 1 |
| Auguste, ME | 1 |
| Benedetto, PW | 2 |
| Fleishman, SB | 1 |
| Lavin, MR | 1 |
| Sattler, M | 1 |
| Szarka, H | 1 |
| Priestman, TJ | 2 |
| Roberts, JT | 1 |
| Upadhyaya, BK | 1 |
| Wellham, LL | 1 |
| McPhee, G | 1 |
| Anac, SY | 1 |
| Ardalan, B | 1 |
| Hesketh, PJ | 1 |
| Roman, A | 1 |
| Hesketh, AM | 1 |
| Perez, EA | 1 |
| Edelman, M | 1 |
| Gandara, DR | 1 |
| Mou, C | 1 |
| Stein, WD | 1 |
| Lyubimov, E | 1 |
| Hu, YP | 1 |
| Fernandez, H | 1 |
| Friedman, CJ | 1 |
| Burris, HA | 1 |
| Yocom, K | 1 |
| Blackburn, LM | 1 |
| Gruben, D | 1 |
| Raschko, JW | 1 |
| Synold, TW | 1 |
| Chow, W | 1 |
| Coluzzi, P | 1 |
| Hamasaki, V | 1 |
| Leong, LA | 1 |
| Margolin, KA | 1 |
| Morgan, RJ | 1 |
| Shibata, SI | 1 |
| Somlo, G | 1 |
| Tetef, ML | 1 |
| Yen, Y | 1 |
| ter Veer, A | 1 |
| Doroshow, JH | 1 |
| Klepp, O | 1 |
| Herman, TS | 1 |
| Einhorn, LH | 1 |
| Jones, SE | 1 |
| Nagy, C | 1 |
| Chester, AB | 1 |
| Dean, JC | 1 |
| Furnas, B | 1 |
| Williams, SD | 1 |
| Leigh, SA | 1 |
| Dorr, RT | 1 |
| Moon, TE | 1 |
| Jarvik, ME | 1 |
| Oliver, IN | 1 |
| Reynolds, S | 1 |
| Rischin, D | 1 |
| Buchanan, L | 1 |
| Tan, LG | 1 |
| Nahata, MC | 1 |
| Ford, C | 1 |
| Ruymann, FB | 1 |
| Chambers, EJ | 1 |
| Akhtar, SS | 1 |
| Bano, ZA | 1 |
| Bhat, GM | 1 |
| Bhat, MA | 1 |
| Goldstein, D | 1 |
| Levi, JA | 1 |
| Woods, RL | 1 |
| Russell, J | 1 |
| Morgan, J | 1 |
| Kerestes, Z | 1 |
| Cunningham, D | 1 |
| Bradley, CJ | 1 |
| Forrest, GJ | 1 |
| Hutcheon, AW | 1 |
| Adams, L | 1 |
| Sneddon, M | 1 |
| Harding, M | 1 |
| Kerr, DJ | 1 |
| Soukop, M | 1 |
| Kaye, SB | 1 |
| Yosselson-Superstine, S | 1 |
| Lipman, AG | 1 |
| Sanders, SH | 1 |
| Murakami, M | 1 |
| Ota, K | 1 |
| Moertel, CG | 1 |
| Reitemeier, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer Receiving 5-day Cisplatin C[NCT05244577] | Phase 3 | 75 participants (Anticipated) | Interventional | 2022-01-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for prochlorperazine and Neoplasms
| Article | Year |
|---|---|
In vitro anticancer activity of fluphenazine, perphenazine and prochlorperazine. A review.
Topics: Antineoplastic Agents; Antipsychotic Agents; Dopamine Antagonists; Drug Repositioning; Fluphenazine; | 2021 |
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cannabinoids; Chlorpromazine; Dizziness; Domperidone; Eup | 2015 |
Radiotherapy in paediatric practice.
Topics: Child; Humans; Neoplasms; Palliative Care; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prochlorp | 1991 |
[Recent advances in the management of chemotherapy-induced emesis].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Domperidone; Dronabinol; Drug Therapy, | 1986 |
20 trials available for prochlorperazine and Neoplasms
| Article | Year |
|---|---|
Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.
Topics: Adult; Aged; Antineoplastic Agents; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Ag | 1980 |
Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine.
Topics: Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Agents; Clinical Trials a | 1982 |
Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1984 |
Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Child; Clinical Trials as Topic; Dronab | 1980 |
Dexamethasone in the treatment of nausea and vomiting from cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Double-Blind Method; Dr | 1981 |
Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Metoclo | 1981 |
Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; C | 1994 |
A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Neop | 1993 |
Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.
Topics: Aged; Aged, 80 and over; Doxorubicin; Drug Administration Schedule; Drug Interactions; Drug Resistan | 1993 |
Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; | 2000 |
Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Survival; Colonic Neoplasms; Culture Media; D | 2000 |
Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Cycl | 2000 |
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2000 |
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Dronabinol; D | 1979 |
A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; | 1992 |
A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis.
Topics: Adult; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mal | 1991 |
Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Double-Blind Method; Fe | 1989 |
A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Dexamethasone; Dronabinol | 1988 |
Adjunctive antianxiety agents in the management of chronic pain.
Topics: Adult; Aged; Analgesics; Anti-Anxiety Agents; Arthritis; Chlordiazepoxide; Chronic Disease; Double-B | 1985 |
Controlled studies of metopimazine for the treatment of nausea and vomiting.
Topics: Antiemetics; Clinical Trials as Topic; Fluorouracil; Humans; Isonipecotic Acids; Nausea; Neoplasms; | 1973 |
20 other studies available for prochlorperazine and Neoplasms
| Article | Year |
|---|---|
Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxi | 2020 |
Influence of cytochrome P450 genotype on the plasma disposition of prochlorperazine metabolites and their relationships with clinical responses in cancer patients.
Topics: Aged; Antiemetics; Cytochrome P-450 Enzyme System; Dopamine Antagonists; Female; Genotype; Humans; M | 2018 |
[A study on the antiemetic effect and extrapyramidal symptoms of prochlorperazine versus perospirone for the control of nausea and vomiting due to opioid introduction].
Topics: Antiemetics; Basal Ganglia Diseases; Female; Humans; Isoindoles; Male; Middle Aged; Nausea; Neoplasm | 2013 |
Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients.
Topics: Aged; Antiemetics; Female; Genetic Variation; Humans; Male; Middle Aged; Multivariate Analysis; Naus | 2014 |
Incidence of nausea and vomiting induced by oxycodone administered with prochlorperazine in Japanese cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Female; Humans; Incidence; Japan; M | 2015 |
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.
Topics: Analgesics, Opioid; Antiemetics; Benzodiazepines; Chemoprevention; Domperidone; Health Care Surveys; | 2015 |
Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Lora | 2016 |
Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry.
Topics: Chromatography, Liquid; Drug Stability; Humans; Neoplasms; Prochlorperazine; Reproducibility of Resu | 2012 |
[Use of prochlorperazine as adjuvant in therapy of secondary phenomena in cancer patients].
Topics: Humans; Neoplasms; Phenothiazines; Prochlorperazine; Spasm; Vomiting | 1959 |
[Prochlorperazine in obstetrics and gynecology].
Topics: Female; Genitalia; Genitalia, Female; Gynecology; Humans; Neoplasms; Obstetrics; Pregnancy; Pregnanc | 1959 |
FURTHER STUDIES CONCERNING CARCINOLYSIS.
Topics: Animals; Antineoplastic Agents; Blood; Carcinoma, Ehrlich Tumor; DNA; DNA, Neoplasm; Mice; Neoplasms | 1963 |
TRACER STUDIES ON A TRANSPLANTABLE HAMSTER MELANOMA.
Topics: Animals; Chlorpromazine; Cricetinae; Eye Neoplasms; Fluoresceins; Idoxuridine; Iodine Isotopes; Mela | 1964 |
Unexpectedly high prevalence of akathisia in cancer patients.
Topics: Akathisia, Drug-Induced; Antiemetics; Female; Humans; Male; Middle Aged; Neoplasms; Palliative Care; | 2007 |
[Vomiting accompanying cytostatic treatment, and its control].
Topics: Antiemetics; Antineoplastic Agents; Dronabinol; Drug Evaluation; Histamine H1 Antagonists; Humans; M | 1984 |
Marihuana for nausea and vomiting due to cancer chemotherapy.
Topics: Dronabinol; Drug-Related Side Effects and Adverse Reactions; Humans; Nausea; Neoplasms; Prochlorpera | 1980 |
Antiemetic-induced akathisia in cancer patients receiving chemotherapy.
Topics: Akathisia, Drug-Induced; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Male; Met | 1994 |
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists.
Topics: Antiemetics; Clinical Trials as Topic; Dopamine Antagonists; Humans; Metoclopramide; Nausea; Neoplas | 1996 |
[Cytostatic treatment and nausea-suppressing agents].
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Neoplasms; Prochlorperazine | 1979 |
Necessary risks.
Topics: Animals; Antiemetics; Dogs; Dronabinol; Drug Industry; Drug-Related Side Effects and Adverse Reactio | 1979 |
Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy.
Topics: Adolescent; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Humans; Infant; Neoplasms; Prochlo | 1992 |